Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Napp Pharmaceutical Group Ltd.

Latest From Napp Pharmaceutical Group Ltd.

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Europe Ripe For Broader Biologic Use In Inflammatory Conditions

The uptake in Europe of biosiomilar infliximab (versions of Janssen's blockbuster Remicade) for inflammatory diseases like rheumatoid arthritis and psoriasis has been patchy to date. In some countries of northern Europe, notably Norway, Denmark and the Netherlands, the biosimilar has been embraced and is capturing the large part of the infliximab market. In other parts of Europe, such as the UK, biosimilar developers report frustration at the lack of movement from the branded product.

Dermatology Cancer

NICE Recommends Biosimilar Infliximab For RA

NICE, the health technology appraisal institute for England and Wales, looks set to recommend biosimilar versions of Merck's Remicade (infliximab) – Napp's Remsima and Hospira's Inflectra – as well as the originator, for some NHS patients with rheumatoid arthritis.

Gastrointestinal Orthopedics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Napp Pharmaceutical Group Ltd.
  • Senior Management
  • Contact Info
  • Napp Pharmaceutical Group Ltd.
    Phone: (44) 1223 424444
    Cambridge Science Park
    Milton Rd.
    Cambridge CB4 4GW,